Teriparatide
As of the edition of 20 October 2026, Teriparatide is a protein: marketed, first approved in 1987 (US); acts on PTH1R; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Protein
- Brand name
- Parathar
- First approved
- 23 December 1987 (US)
- Approvals on record
- 18 in 5 regions
- Holder of the most recent approval
- Apsen Farmaceutica; 12 holders in all
- Withdrawn from market
- 24 November 2020 (in some regions)
- Registered trials
- 112, 10 stopped early
- Disease areas
- Bones, joints and muscles; Nutrition and metabolism; Injuries; Hormones; Nervous system; Pregnancy and women's health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
3 companies on route B because of this drug.
Companies on route B for this drug
In the product3 companies are on route B because of Teriparatide.
See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTH1R | Parathyroid hormone/parathyroid hormone-related peptide receptor | Q03431 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 21 | 12 | 6 | 2 |
| Phase 1 | 12 | 9 | 1 | 1 |
| Phase 2 | 25 | 15 | 1 | 5 |
| Phase 3 | 24 | 22 | 0 | 1 |
| Phase 4 | 30 | 22 | 2 | 1 |
| All trials | 112 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant | 1987 to now |
| Eli Lilly | Applicant, Later holder and Lead sponsor of trials | 1996 to now |
| Asahi Kasei Therapeutics | Applicant | 2011 to now |
| Ligand Pharmaceuticals | Later holder and Lead sponsor of trials | 2015 to now |
| Alvogen | Acquired holder | 2020 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2022 to now |
| Almaject | Later holder | 2024 to now |
| Apsen Farmaceutica | Applicant | 2026 to now |